Results 141 to 150 of about 2,622 (185)

Kinetics of intestinal ultrasound and shear-wave elastography to assess early response in ulcerative colitis patients treated with filgotinib. [PDF]

J Crohns Colitis
Pruijt MJ, Teichert C, De Voogd FA, Janssen RJ, Löwenberg M, Goetgebuer RL, D'Haens GR, Gecse KB.   +7 more
europepmc   +1 more source

Tofacitinib-Induced Weight Gain in Context: comment on the article by Wollenhaupt et al. [PDF]

ACR Open Rheumatol
Palmowski A, Buttgereit F, Simon D, Kleyer A, Drzeniek NM.   +4 more
europepmc   +1 more source

Filgotinib Effectiveness in Rheumatoid Arthritis: Observational Analysis of a Large Multicenter Cohort. [PDF]

Rheumatol Ther
Celletti E, Di Penta M, Ariani A, Parisi S, Andracco R, Raffeiner B, Ianniello A, Lo Gullo A, Molica Colella AB, Priora M, Paroli M, Lumetti F, Ravagnani V, Girelli F, Vitetta R, Volpe A, Scolieri P, Bezzi A, Ometto F, Visalli E, Farina A, Del Medico P, Bravi E, Colina M, Larosa M, Serale F, Franchina V, Molica Colella F, Ferrero G, Sandri G, Addimanda O, Reta M, Mascella F, Focherini MC, Fiorenza A, Rovera G, Giampietro C, Bernardi S, Mansueto N, Camellino D, Caccavale R, Nucera V, Sabatini E, Del Biondo P, Ditto MC, Platè I, Adorni G, Di Donato E, Santilli D, Lucchini G, Amato G, De Lucia F, Dal Bosco Y, Foti R, Smerilli G, Bianchi G, Foti R, Arrigoni E, Marchetta A, Bixio R, Bruzzese V, Fusaro E, Giuggioli D, Salvarani C, Cipollone F, Becciolini A.   +65 more
europepmc   +1 more source

Factors Associated with Difficult-to-Treat Rheumatoid Arthritis (D2T-RA): Real-World Evidence from a Single-Center Cross-Sectional Study. [PDF]

J Pers Med
Benucci M, Li Gobbi F, Cassarà EAM, Terenzi R, Cioffi E, D'Elia C, Aliberti S, Guiducci S, Russo E, Lari B, Grossi V, Infantino M, Manfredi M.   +12 more
europepmc   +1 more source

JAK inhibitors in the management of extra-intestinal manifestations in inflammatory bowel disease. [PDF]

Ther Adv Gastroenterol
Fousekis FS, Jefremow A, Katsanos KH, Neurath MF, Atreya R.   +4 more
europepmc   +1 more source

Targeting STAT3 in systemic lupus erythematosus and lupus nephritis: mechanisms, therapeutic advances, and structure-informed perspectives. [PDF]

Front Pharmacol
Yi F, Tu X, Jin R, Zhou J, Li Y, Liao H, Xu W, Yuan Y, Wu M, Bi P, Yin J.   +10 more
europepmc   +1 more source

Filgotinib for the treatment of rheumatoid arthritis [PDF]

Expert Opinion on Investigational Drugs, 2017
Biologics were the first targeted therapies for rheumatoid arthritis (RA), having in common high clinical efficacy. Being proteins, they are administered parenterally. The first oral targeted small molecules approved for RA are competitive inhibitors of the Janus kinase (JAK) enzyme family which mediate signalling for a cytokine subset important in RA ...
Peter C Taylor, Serafim Kiriakidis
exaly   +5 more sources

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial [PDF]

Lancet, The, 2021
BACKGROUND: The global prevalence of ulcerative colitis is increasing, and induction and maintenance of remission is a crucial therapeutic goal. We assessed the efficacy and safety of filgotinib, a once-daily, oral Janus kinase 1 preferential inhibitor ...
Brian G Feagan, Silvio Danese, Edward V Loftus   +2 more
exaly   +6 more sources

Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials [PDF]

Modern Rheumatology, 2022
In the treatment of rheumatoid arthritis (RA), Janus kinase inhibitors (jakinibs) represent an emerging class of targeted therapies in addition to biologics.
Yoshiya Tanaka, Arthur Kavanaugh, Iain B Mcinnes   +2 more
exaly   +3 more sources